BLI-489
CAS No. : 623564-40-9
| Size | Price | Stock |
|---|---|---|
| 1mg | $420 | In-stock |
| 5mg | $1605 | In-stock |
| 10mg | $2572 | In-stock |
| 25mg | $5145 | In-stock |
| 50mg | $7977 | In-stock |
| 100 mg | Get quote | |
| 200 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-108062 |
| M.Wt: | 327.29 |
| Formula: | C13H10N3NaO4S |
| Purity: | >98 % |
| Solubility: | DMSO : ≥ 105 mg/mL |
BLI-489 is a Beta-lactamase inhibitor. BLI-489 is an antibacterial adjuvant that significantly enhances the antibacterial efficacy of β-lactam antibiotics. BLI-489 blocks the hydrolytic activity of the enzyme by forming a stable intermediate in serine Beta-lactamase, or by coordinating with the binuclear Zn2+ through an oxygen atom in metallo-Beta-lactamase. BLI-489 can be used for research on bacterial infections[1][2][3][4].
In Vitro:BLI-489 (2-4 μg/mL; 18-22 h) enhances the antibacterial activity of Piperacillin (HY-B1923) against various predicted panels of Gram-negative and Gram-positive bacteria and clinical isolates[1].
BLI-489 (up to 64 µg/mL; 24 h) exhibits synergistic growth inhibition with Ceftriaxone (HY-B0712) in NDM-producing NDM-Kp, with an MIC of 8 μg/mL and an MBC of 16 μg/mL[4].
BLI-489 (4-16 μg/mL; 4-24 h) inhibits biofilm formation in NDM-Kp, does not cause bacterial cell membrane protein leakage, reduces bacterial load, and maintains the integrity of cell surface morphology[4].
BLI-489 (8 mg/L; 24 h) exhibits synergistic antibacterial activity with Imipenem (HY-B1369A) in CRAb strains producing CHDLs and MBLs[2].
BLI-489 (8 mg/L; 6-24 h) in combination with Imipenem shows synergy against OXA-24-like, OXA-51-like, and OXA-58-producing CRAb isolates, but does not show synergy against OXA-23-producing CRAb isolates after 24 h[2].
BLI-489 (4-64 μg/mL; 4 h) exhibits low hemolytic activity and high biocompatibility in red blood cells (RBCs)[4].
In Vivo:BLI-489 (25 mg/kg; i.p.; every 8 h; 3 days) synergizes with Imipenem to improve mouse survival in a CRAb-infected BALB/c mouse pneumonia model[2].
BLI-489 (ED50 dose in combination with Piperacillin ranges from 8.5-69 mg/kg; s.c.; administered at 30 min and 150 min post-infection, 1-2 doses total; observed for 7 days after the first day of dosing) significantly improves survival rates and restores the in vivo efficacy of Piperacillin in CD-1 mouse acute lethal systemic infection models caused by various β-lactamase-producing pathogenic bacteria[3].
BLI-489 (8 mg/L; administered in agar medium; single administration; 24 h) synergizes with Imipenem to improve nematode survival in the CRAb-infected C. elegans model[2].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- BLI-489
- Cat. No.:
- HY-108062
- Quantity:
Your information is safe with us.